What is the half-life of each compound in Omega Meds Cut Mix?

Testosterone Propionate has a plasma half-life of approximately 2 days, Trenbolone Acetate clears in roughly 1–2 days due to its 2-carbon acetate chain, and Drostanolone Propionate follows the propionate ester pattern at approximately 2–3 days. All three compounds are therefore classified as short-esters, with peak plasma concentrations reached within 24 hours of intramuscular administration and near-full clearance by day 5–7 post-injection.

How does the combined release profile of Cut Mix differ from administering the three compounds separately as long-ester versions?

When all three compounds share short propionate or acetate esters, their individual plasma peaks overlap within the same 24-hour post-injection window — creating a synchronised multi-mechanism anabolic signal. Long-ester equivalents (enanthate, decanoate) generate staggered peaks across 3–10 days, making it pharmacokinetically impossible to achieve the same simultaneous receptor engagement from a single injection. Cut Mix's tri-ester co-formulation uniquely replicates this synchronised profile every injection day.

What injection frequency does the pharmacokinetic profile of Cut Mix require?

The short half-lives of all three esters (1–3 days) necessitate injections every other day (EOD) or, at minimum, every 2–3 days to maintain stable plasma concentrations above the threshold needed for sustained anabolic effect. Once-weekly dosing would produce significant plasma troughs between injections, reducing efficacy and causing hormone-level fluctuations inconsistent with a controlled cutting protocol.

Why does the 10×1ml single-dose ampoule format matter for sterility compared to multi-dose vials?

Each 1ml ampoule is a hermetically sealed, single-use unit — once broken open, the entire contents are administered in one injection with no re-entry into the container. This eliminates the particulate and microbial contamination risks that accumulate with repeated needle punctures through a multi-dose vial stopper. For users injecting EOD across a 6–8 week cut, single-dose ampoules provide consistent sterile integrity at every administration point.

Is Cut Mix at 150mg/ml the right concentration for precise per-compound dosing?

At 150mg/ml total — with each of the three compounds contributing exactly 50mg/ml — Cut Mix is the lowest-concentration tri-ester in its competitive category. This makes it the most straightforward option for dose calculation: every 1ml ampoule delivers an unambiguous 50mg of each active compound. Users targeting a specific per-compound dose (e.g. 50mg Trenbolone Acetate EOD) can use whole ampoules without fractional-volume measurement errors that higher-concentration formats introduce. (2) angle_used

Science Focus

Omega Meds

Cut Mix 150mg/ml 10x1ml Ampullen by Omega Meds

Name: Cut Mix 150mg/ml 10x1ml Ampoules by Omega Meds
Brand: Omega Meds
SKU: INJ-MIX-OME-150-010
Price: 59.00 EUR
Availability: InStock

Omega Meds Cut Mix is a 150mg/ml tri-ester injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml and Drostanolone Propionate 50mg/ml — supplied in 10 single-dose 1ml ampoules, formulated around a pharmacokinetically matched short-ester triad in which all three compounds reach peak plasma concentration within 24 hours of intramuscular administration. The acetate and propionate ester chains driving each compound's de-esterification rate produce overlapping clearance windows across a 5–7 day post-injection period, enabling post-cycle therapy to be initiated as early as day 3–5 after the final ampoule. Each production lot is released with HPLC-verified per-compound concentration data and LAL endotoxin clearance confirmation documented at batch level.

€59.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Three mechanistically distinct compounds delivered via one depot — propionate and acetate esters ensure plasma peaks align within a single 24-hour window.
Short ester chain lengths enable a PCT start date as early as day 3–5 post-cycle, minimising recovery delay.
Drostanolone Propionate's intrinsic anti-oestrogenic properties reduce oestrogenic side-effect burden during the ester-active window without a separate AI.
10×1ml single-dose glass ampoules preserve sterility at every injection point across an EOD dosing schedule.
At 50mg per compound per ampoule, dose titration is straightforward — whole ampoules correspond directly to per-compound targets.
Trenbolone Acetate's rapid de-esterification (1–2 day half-life) allows meaningful mid-cycle dosage adjustments not possible with long-ester variants.
Analytically validated: HPLC-confirmed concentrations and LAL endotoxin testing applied per batch, documented at release.

Phase	dosage	Note
Introductory / Sensitivity Assessment	0.5ml EOD (75mg total / 25mg per compound)	Allows pharmacokinetic response monitoring across the short 1–3 day half-life window before full-dose commitment; peak plasma reached within 24 hours of first injection.
Main Cutting Phase	1ml EOD (150mg total / 50mg per compound)	EOD frequency maintains plasma levels above trough by respecting the ~2-day propionate/acetate half-life; standard duration 6–8 weeks.
Final Week (Ester Clearance Phase)	0.5ml EOD tapering to final dose	Tapering in the final 5–7 days aligns with short-ester clearance kinetics; the rapid de-esterification of acetate and propionate chains means plasma levels fall measurably within 48 hours of dose reduction.
PCT Initiation	Day 3–5 after last injection	Short carbon-chain esters clear sufficiently by day 3–5 to allow SERM therapy to begin; aggressive SERM protocol is mandatory given the tri-compound suppression profile.

Key takeaways

Match injection frequency to the 1–3 day ester half-lives for stable plasma levels.
Expect all three compound peaks to converge within 24 hours of each injection.
Begin PCT planning 3–5 days after the final ampoule based on short-ester clearance.
Use single-dose ampoules to eliminate multi-puncture contamination across the cycle.
Verify per-compound potency via the HPLC batch documentation at 50mg/ml each.

Pharmacokinetic Architecture of a Three-Ester Cutting Blend

Omega Meds Cut Mix is a precisely engineered tri-ester injectable formulation in which three short-chain esters — Testosterone Propionate, Trenbolone Acetate and Drostanolone Propionate, each at 50mg/ml — are co-dissolved at 150mg/ml total concentration to deliver overlapping but mechanistically distinct plasma release profiles from a single 1ml ampoule. This architecture is the defining pharmacokinetic feature that separates a purpose-built cut stack from any collection of individual short-ester injections given on the same day: ester hydrolysis kinetics converge in one depot rather than across multiple injection sites, producing a tighter, more synchronised anabolic signal window.

Half-Life Profiles and What They Mean in Practice

Testosterone Propionate carries an estimated plasma half-life of approximately 2 days (de-esterification measured via radioimmunoassay studies on propionate esters), Trenbolone Acetate clears with a half-life of roughly 1–2 days due to the 2-carbon acetate chain's rapid enzymatic hydrolysis, and Drostanolone Propionate mirrors the propionate pattern at approximately 2–3 days. Compared to enanthate or decanoate esters — which generate depot half-lives of 4–10 days — all three compounds in Cut Mix reach peak plasma concentration within 24 hours post-injection and clear the system within 5–7 days of the final dose. This rapid de-esterification timeline is what enables a post-cycle therapy window to open as early as 3–5 days after the last ampoule, a meaningful clinical advantage over long-ester cutting stacks.

Release Synchronisation: Three Mechanisms, One Injection

The pharmacokinetic value of Cut Mix extends beyond convenience. Testosterone Propionate functions as the aromatising androgenic base, maintaining physiological androgen receptor occupancy throughout the depot window. Trenbolone Acetate delivers non-aromatising 19-nor anabolic signalling — with a binding affinity approximately five times that of testosterone at the androgen receptor — peaking within the same 24-hour plasma window as the propionate esters. Drostanolone Propionate, a DHT-derived compound with intrinsic anti-oestrogenic properties, contributes a third mechanistic layer: it competes with oestradiol at peripheral sites, supporting a drier, more defined body composition outcome without requiring an additional standalone aromatase inhibitor during the short ester window. All three compounds peak, act and clear in near-simultaneous fashion — a pharmacokinetic alignment that is structurally impossible to replicate by administering the same three compounds as long-ester variants on different injection schedules.

Ampoule Format and Analytical Quality Standards

Omega Meds supplies Cut Mix in 10×1ml glass ampoules, each constituting a single-dose sterile unit. The single-dose ampoule format eliminates the repeated-puncture contamination risk inherent in multi-dose vials and is consistent with GMP fill-finish standards for injectable pharmaceuticals. Each production batch undergoes HPLC quantification to confirm all three per-compound concentrations at the declared 50mg/ml level, with LAL (Limulus Amebocyte Lysate) endotoxin testing applied as the standard bacterial contamination screen. At 150mg/ml total concentration — the lowest in its product category — Cut Mix prioritises per-compound dosing precision over volume compression, making it the analytically conservative choice for users who calibrate their cycles to specific compound-level targets.

Usage

Calculate your target per-compound dose first — at 50mg/ml per active ingredient, each 1ml ampoule delivers a fixed and unambiguous amount of Testosterone Propionate, Trenbolone Acetate and Drostanolone Propionate, so build your EOD schedule around whole-ampoule or half-ampoule volumes.
Store ampoules at 15–25°C away from direct light; the oil solution in sealed glass ampoules remains stable across the declared shelf-life at this temperature range — inspect visually for particulate before each use.
Break the ampoule using the score mark, draw the full volume into a sterile syringe with a drawing needle (18–21G), then switch to an injection needle (23–25G) to reduce particulate carry-over from the ampoule neck.
Administer intramuscularly into a large muscle group (glute, lateral quad or deltoid); given the EOD injection frequency dictated by short ester half-lives, rotate sites systematically — log each injection site and date.
Inject slowly and steadily; because Trenbolone Acetate is one of the three active compounds, maintain a controlled plunger rate and aspirate if your protocol requires it — monitor for any atypical respiratory sensation post-injection.
Track plasma-level timing: peak concentration occurs within approximately 24 hours of each injection, with meaningful decline beginning by 48–60 hours — use this window to assess subjective response and time any ancillary compound administration accordingly.

Warnings

Contraindications: Cut Mix is contraindicated in individuals with prostate or breast carcinoma, existing hepatic or renal dysfunction, uncontrolled cardiovascular disease, or hypersensitivity to any of the three active compounds or carrier oil components. Women and adolescents must not use this product. The presence of Trenbolone Acetate adds a 19-nor progestogenic dimension that makes this combination unsuitable for individuals with a personal or family history of prolactin-dependent conditions.

Side Effects: Androgenic side effects — including accelerated scalp hair thinning in genetically predisposed individuals, acne and elevated sebum production — are possible across all three compounds given their DHT-related or androgenic activity. Trenbolone Acetate may cause sleep disturbance, elevated perspiration and cardiovascular strain (elevated resting heart rate, reduced aerobic work capacity). Drostanolone Propionate can amplify androgenic effects via SHBG displacement. Oestrogenic side effects are possible via the Testosterone Propionate component; monitor for gynecomastia and water retention.

Monitoring: Haematological markers (haematocrit, haemoglobin), lipid panel (LDL/HDL), blood pressure and liver enzymes should be assessed at baseline, at cycle midpoint and at PCT initiation. Prolactin levels warrant monitoring given Trenbolone Acetate's 19-nor pharmacology. Because all three esters clear within 5–7 days of the final injection, bloodwork timing post-cycle should account for residual androgenic suppression persisting beyond ester clearance.

PCT: Given the tri-compound HPG axis suppression — from testosterone, a 19-nor anabolic and a DHT derivative simultaneously — an aggressive SERM-based post-cycle protocol is mandatory. PCT can begin as early as 3–5 days after the last injection, consistent with the short-ester pharmacokinetic clearance data. SERM selection and duration should reflect the depth of suppression over the cycle length; consult an endocrinologist or sports medicine physician before initiating.

Frequently asked questions

What is the half-life of each compound in Omega Meds Cut Mix?: Testosterone Propionate has a plasma half-life of approximately 2 days, Trenbolone Acetate clears in roughly 1–2 days due to its 2-carbon acetate chain, and Drostanolone Propionate follows the propionate ester pattern at approximately 2–3 days. All three compounds are therefore classified as short-esters, with peak plasma concentrations reached within 24 hours of intramuscular administration and near-full clearance by day 5–7 post-injection.
How does the combined release profile of Cut Mix differ from administering the three compounds separately as long-ester versions?: When all three compounds share short propionate or acetate esters, their individual plasma peaks overlap within the same 24-hour post-injection window — creating a synchronised multi-mechanism anabolic signal. Long-ester equivalents (enanthate, decanoate) generate staggered peaks across 3–10 days, making it pharmacokinetically impossible to achieve the same simultaneous receptor engagement from a single injection. Cut Mix's tri-ester co-formulation uniquely replicates this synchronised profile every injection day.
What injection frequency does the pharmacokinetic profile of Cut Mix require?: The short half-lives of all three esters (1–3 days) necessitate injections every other day (EOD) or, at minimum, every 2–3 days to maintain stable plasma concentrations above the threshold needed for sustained anabolic effect. Once-weekly dosing would produce significant plasma troughs between injections, reducing efficacy and causing hormone-level fluctuations inconsistent with a controlled cutting protocol.
Why does the 10×1ml single-dose ampoule format matter for sterility compared to multi-dose vials?: Each 1ml ampoule is a hermetically sealed, single-use unit — once broken open, the entire contents are administered in one injection with no re-entry into the container. This eliminates the particulate and microbial contamination risks that accumulate with repeated needle punctures through a multi-dose vial stopper. For users injecting EOD across a 6–8 week cut, single-dose ampoules provide consistent sterile integrity at every administration point.
Is Cut Mix at 150mg/ml the right concentration for precise per-compound dosing?: At 150mg/ml total — with each of the three compounds contributing exactly 50mg/ml — Cut Mix is the lowest-concentration tri-ester in its competitive category. This makes it the most straightforward option for dose calculation: every 1ml ampoule delivers an unambiguous 50mg of each active compound. Users targeting a specific per-compound dose (e.g. 50mg Trenbolone Acetate EOD) can use whole ampoules without fractional-volume measurement errors that higher-concentration formats introduce. (2) angle_used

Manufacturer

Quality assurance at Omega Meds is applied as a compound-specific discipline rather than a uniform production checklist — for Cut Mix, this means each batch of the tri-ester oil solution must satisfy independent analytical criteria for all three active compounds before release, not a single composite potency test. The production environment operates under GMP-aligned conditions with defined environmental monitoring for particulates and microbial contamination across the fill-finish zone. ISO-compliant raw material specifications govern the acceptance of each API lot — Testosterone Propionate, Trenbolone Acetate and Drostanolone Propionate are each tested against identity and purity criteria by HPLC prior to compounding, ensuring that the 50mg/ml per-compound concentration documented on the certificate of analysis reflects verified analytical reality rather than a nominal label claim. LAL endotoxin testing is applied to finished injectable lots as the standard pyrogen screen, with batch release conditional on passing the defined endotoxin limit. This multi-stage analytical gatekeeping reflects Omega Meds' recognition that a tri-ester injectable in the ampoule format carries a higher per-unit quality burden — because there is no mid-batch correction opportunity once single-dose ampoules are sealed and released.

Product details

Brand	Omega Meds
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Gain Mix, Omega Meds Steroid-Mix
Strength	150 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-MIX-OME-150-010

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00